CN116920039B - Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof - Google Patents
Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof Download PDFInfo
- Publication number
- CN116920039B CN116920039B CN202210337079.1A CN202210337079A CN116920039B CN 116920039 B CN116920039 B CN 116920039B CN 202210337079 A CN202210337079 A CN 202210337079A CN 116920039 B CN116920039 B CN 116920039B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- filtrate
- rhizoma
- mixing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 208000031226 Hyperlipidaemia Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title abstract description 33
- 239000000706 filtrate Substances 0.000 claims abstract description 37
- 241000756943 Codonopsis Species 0.000 claims abstract description 35
- 238000002156 mixing Methods 0.000 claims abstract description 27
- 239000006041 probiotic Substances 0.000 claims abstract description 27
- 235000018291 probiotics Nutrition 0.000 claims abstract description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000008517 radix Trichosanthis Substances 0.000 claims abstract description 23
- 238000001914 filtration Methods 0.000 claims abstract description 22
- 239000000843 powder Substances 0.000 claims abstract description 22
- 210000000582 semen Anatomy 0.000 claims abstract description 20
- 239000000052 vinegar Substances 0.000 claims abstract description 16
- 235000021419 vinegar Nutrition 0.000 claims abstract description 16
- 230000000529 probiotic effect Effects 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 238000002791 soaking Methods 0.000 claims abstract description 14
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 12
- 238000001035 drying Methods 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims description 13
- 235000008599 Poria cocos Nutrition 0.000 claims description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 11
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 11
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 11
- 240000001417 Vigna umbellata Species 0.000 claims description 11
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 11
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 10
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims description 9
- 235000008658 Artemisia capillaris Nutrition 0.000 claims description 4
- 241000092668 Artemisia capillaris Species 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 2
- 239000000047 product Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 15
- 150000002632 lipids Chemical class 0.000 abstract description 7
- 230000007774 longterm Effects 0.000 abstract description 5
- 241000007126 Codonopsis pilosula Species 0.000 abstract description 4
- 206010067484 Adverse reaction Diseases 0.000 abstract description 3
- 206010039020 Rhabdomyolysis Diseases 0.000 abstract description 3
- 230000006838 adverse reaction Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 12
- 208000004880 Polyuria Diseases 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 11
- 230000035619 diuresis Effects 0.000 description 11
- 230000001737 promoting effect Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 210000004072 lung Anatomy 0.000 description 9
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 235000009508 confectionery Nutrition 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 241000721047 Danaus plexippus Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 235000009818 Trichosanthes kirilowii Nutrition 0.000 description 3
- 240000006023 Trichosanthes kirilowii Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000001603 reducing effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241000748223 Alisma Species 0.000 description 2
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 240000001851 Artemisia dracunculus Species 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030302 Oliguria Diseases 0.000 description 2
- 241001522129 Pinellia Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 2
- 206010039424 Salivary hypersecretion Diseases 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 208000026451 salivation Diseases 0.000 description 2
- 229960002855 simvastatin Drugs 0.000 description 2
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000004647 tinea pedis Diseases 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 229940126673 western medicines Drugs 0.000 description 2
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 241000209514 Alismataceae Species 0.000 description 1
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000605447 Anemarrhena Species 0.000 description 1
- 235000003097 Artemisia absinthium Nutrition 0.000 description 1
- 235000003092 Artemisia dracunculus Nutrition 0.000 description 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 1
- 244000020518 Carthamus tinctorius Species 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 244000008991 Curcuma longa Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 1
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000237903 Hirudo Species 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000003889 Paeonia suffruticosa Nutrition 0.000 description 1
- 240000005001 Paeonia suffruticosa Species 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 235000018167 Reynoutria japonica Nutrition 0.000 description 1
- 240000001341 Reynoutria japonica Species 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 240000007164 Salvia officinalis Species 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229930191283 anemarrhena Natural products 0.000 description 1
- 239000001138 artemisia absinthium Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 235000005412 red sage Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/884—Alismataceae (Water-plantain family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicines, and in particular relates to a composition for treating hyperlipidemia and a preparation method thereof. The raw materials of the composition comprise the following components: rhizoma anemarrhenae, cortex moutan, alismatis rhizoma, poria, radix Stephaniae Tetrandrae, herba Lycopi, trichosanthis radix, radix Codonopsis, herba Artemisiae Scopariae and semen Phaseoli. The preparation method comprises soaking cortex moutan, alismatis rhizoma, and Poria in vinegar, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, extracting with water, and filtering to obtain residue 1 and filtrate 1; mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, part of radix Codonopsis and semen Phaseoli, extracting with water, and filtering to obtain filtrate 2; and finally, mixing the filtrate 1 and the filtrate 2, concentrating, adding the rest codonopsis pilosula powder, mixing, adding the probiotic powder for fermentation, and drying to obtain the Chinese medicinal preparation. The composition has outstanding efficacy in lipid lowering, avoids the risks of adverse reactions such as rhabdomyolysis and the like caused by taking chemical medicines, has good compliance of patients, and is suitable for long-term taking.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine preparations and preparation, and in particular relates to a traditional Chinese medicine composition for treating hyperlipidemia and a preparation method thereof.
Background
Hyperlipidemia refers to the condition that fat metabolism or operation is abnormal so that the blood fat content in human blood exceeds a normal range, the condition is that cholesterol and/or triglyceride in blood are too high or high density lipoprotein is too low, and the hyperlipidemia is called as 'dyslipidemia', is a disease of abnormally increased blood fat level caused by in vivo fat metabolism or operation abnormality, is an independent risk factor for atherosclerosis and cardiovascular and cerebrovascular diseases, and is an important way for preventing cardiovascular and cerebrovascular diseases. Most lipid-lowering western medicines mainly comprise statin drugs and fibrate drugs, and have therapeutic effects, but adverse reactions such as liver and kidney damage, rhabdomyolysis and the like generally exist, so that the compliance of patients is greatly reduced.
The traditional Chinese medicine has certain advantages in treating hyperlipidemia, and has the advantages of regulating blood lipid change on the whole through multiple components and multiple targets, and having small toxic and side effects compared with western medicines.
For example, the Chinese patent application CN201410101019.5 discloses a Chinese medicinal preparation for reducing blood fat and promoting blood circulation, which comprises the following raw material medicaments in part by weight: 50-200 parts of lotus leaf, 30-150 parts of red silk thread, 20-200 parts of ginkgo leaf, 10-60 parts of rhizoma alismatis, 10-60 parts of red sage root, 10-60 parts of pseudo-ginseng, 10-50 parts of semen cassiae, 10-30 parts of radix puerariae, 30-180 parts of fructus crataegi, 10-50 parts of gynostemma pentaphylla and 10-100 parts of rhizoma smilacis glabrae. The invention has the effects of promoting blood circulation, removing blood stasis, dredging meridian passage, and can be used for treating hyperlipidemia, blood viscosity reduction, blood vessel softening, blood lipid regulation, head distention, dizziness, obesity, uric acid high and other symptoms caused by hyperlipidemia. Has small toxic and side effects, can quickly and stably reduce blood fat and promote blood circulation, and solves the problem of difficult medicine taking of patients with hyperlipidemia for life. The invention claims to have excellent hypolipidemic effect, but the drug effect is not shown by a few cases through scientific experimental study, and has no universality.
Another chinese patent application CN200710019016.7 discloses a traditional Chinese medicine for treating hyperlipidemia, which is prepared from the following raw materials in parts by weight: 30.0 to 60.0 portions of astragalus root, 6.0 to 20.0 portions of peach kernel, 6.0 to 15.0 portions of safflower, 15.0 to 30.0 portions of fleece-flower root, 10.0 to 30.0 portions of alisma, 10.0 to 30.0 portions of hawthorn, 6.0 to 15.0 portions of pinellia tuber, 6.0 to 15.0 portions of dried orange peel, 10.0 to 30.0 portions of poria cocos, 3.0 to 10.0 portions of liquorice, 6.0 to 20.0 portions of bamboo shavings and 6.0 to 20.0 portions of immature bitter orange. For the combined hyperviscosity, adding Lumbricus 10.0-20.0, and Hirudo 3.0-9.0. For combined fatty liver disease, rhizoma Polygoni Cuspidati 10.0-20.0 and semen Cassiae 10.0-20.0 are added. The invention has obvious curative effect on treating hyperlipoidemia, but the invention contains the pinellia tuber which is a toxic medicinal material and is not suitable for long-term administration of patients with chronic cardiovascular diseases.
Therefore, although the traditional Chinese medicine has a certain effect in lipid-lowering, the traditional Chinese medicine has the problems of insufficient efficacy, insufficient utilization rate of medicinal materials and inapplicability to long-term administration.
Disclosure of Invention
Aiming at the defects of the technology, the invention provides a traditional Chinese medicine composition for treating hyperlipidemia. The traditional Chinese medicine has good lipid-lowering effect, simple medicine taste, high medicine utilization rate and no toxic or side effect.
In order to achieve the purpose of the invention, the technical scheme adopted is as follows:
A composition for treating hyperlipidemia, the raw materials of the composition comprise the following components: rhizoma anemarrhenae, cortex moutan, alismatis rhizoma, poria, radix Stephaniae Tetrandrae, herba Lycopi, trichosanthis radix, radix Codonopsis, herba Artemisiae Scopariae and semen Phaseoli.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 1-10 parts of rhizoma anemarrhenae, 3-8 parts of cortex moutan, 1-10 parts of rhizoma alismatis, 1-5 parts of poria cocos, 1-5 parts of radix stephaniae tetrandrae, 1-5 parts of herba lycopi, 1-5 parts of radix trichosanthis, 1-10 parts of radix codonopsis, 1-10 parts of artemisia capillaris and 1-5 parts of red bean.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 1-5 parts of rhizoma anemarrhenae, 3-5 parts of cortex moutan, 3-8 parts of rhizoma alismatis, 2-4 parts of poria cocos, 2-4 parts of radix stephaniae tetrandrae, 1-3 parts of herba lycopi, 1-5 parts of radix trichosanthis, 3-8 parts of radix codonopsis, 3-8 parts of artemisia capillaris and 1-5 parts of red bean.
Preferably, the raw materials of the composition comprise the following components in parts by weight: 5 parts of rhizoma anemarrhenae, 4.2 parts of moutan bark, 5 parts of rhizoma alismatis, 2.8 parts of poria cocos, 2.8 parts of radix stephaniae tetrandrae, 2 parts of herba lycopi, 1.4 parts of radix trichosanthis, 5 parts of radix codonopsis, 5.6 parts of herba artemisiae scopariae and 1.4 parts of red bean.
The traditional Chinese medicine has the following efficacy:
Rhizoma anemarrhenae is dry rhizome of rhizoma anemarrhenae of Liliaceae. It enters lung, stomach and kidney meridians. Bitter, sweet and cold. Clearing heat and purging fire, promoting fluid production and moistening dryness. Can be used for treating exogenous febrile disease, hyperpyrexia, polydipsia, lung heat, dry cough, hectic fever, internal heat, diabetes, constipation, and intestinal dryness.
Cortex moutan is dry root bark of Paeonia suffruticosa of Ranunculaceae. It enters heart, liver and kidney meridians. Bitter and pungent, and slightly cold. Clear heat and cool blood, activate blood and remove stasis. Can be used for treating toxic heat, speckle, hematemesis, epistaxis, night fever, early cooling, sweating, bone steaming, amenorrhea, dysmenorrhea, carbuncle, skin sore, and traumatic injury.
The Alismatis rhizoma is dry tuber of Alismatis rhizoma of Alismataceae. Enter kidney and bladder meridians. Sweet and cold. Promoting urination, and clearing damp-heat. Can be used for treating difficult urination, edema, distention, diarrhea, oliguria, dizziness due to phlegm and fluid retention, and stranguria due to heat.
Poria is dried sclerotium of Poria cocos (Roxb.) wolf belonging to Polyporaceae. It enters heart, lung, spleen and kidney meridians. Sweet, light and flat. Induce diuresis and excrete dampness, invigorate spleen and calm heart. Can be used for treating edema, oliguria, phlegm retention, palpitation, spleen deficiency, anorexia, loose stool, diarrhea, uneasiness, palpitation, and insomnia.
Radix Stephaniae Tetrandrae is dry root of radix Stephaniae Tetrandrae. Enter bladder and lung meridians. Bitter and cold. Induce diuresis to alleviate edema, dispel wind and alleviate pain. Can be used for treating edema, tinea pedis, dysuria, eczema, skin sore, and rheumatalgia.
Herba Lycopi is dry aerial part of sweet potato seedling of Labiatae. Enter liver and spleen meridians. Bitter and pungent, and slightly warm. Promoting blood circulation to remove blood stasis, and inducing diuresis to alleviate edema. Can be used for treating menoxenia, amenorrhea, dysmenorrhea, puerperal abdominal pain due to blood stasis, and edema.
Radix Trichosanthis is dry root of Trichosanthes kirilowii Maxim or Trichosanthes kirilowii Maxim of Cucurbitaceae. Enter lung and stomach meridians. Sweet, slightly bitter and slightly cold. Clearing heat and promoting salivation, detumescence and expelling pus. Can be used for treating pyretic polydipsia, lung heat dryness cough, internal heat diabetes, and pyocutaneous disease.
Radix Codonopsis is dry root of radix Codonopsis Lanceolatae (Codonopsis pilosula Miq. Of Campanulaceae) plant essence flower or radix Codonopsis Lanceolatae. Enter spleen and lung meridians. Sweet and flat. Tonify middle energizer and qi, strengthen spleen and lung. Can be used for treating spleen and lung weakness, short breath, palpitation, anorexia, loose stool, asthma, cough, internal heat, and diabetes.
Herba Artemisiae Scopariae is herba Artemisiae Scopariae with fruit ear collected in autumn. Enters the liver, spleen and bladder meridians. Bitter and pungent, cool. Clear heat and promote diuresis. For jaundice due to damp-heat, difficult urination, wind-itching, sore and scabies.
The semen Phaseoli is dry mature seed of semen Phaseoli or semen Phaseoli of Leguminosae. It enters heart and small intestine meridians. Sweet, sour, flat. Induce diuresis to alleviate edema, detoxify and expel pus. Can be used for treating edema, tinea pedis, edema of limbs, jaundice, dark urine, rheumatic arthralgia, carbuncle, skin sore, and abdominal pain.
It is still another object of the present invention to provide a method for preparing the above composition, comprising the steps of:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar, filtering, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, extracting with water, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, part of radix Codonopsis and semen Phaseoli, extracting with water, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotics, fermenting, and drying.
Preferably, the temperature of the soaking with vinegar in the step (1) is 40-55 ℃, and the soaking time is 40-60min.
Preferably, 0.05-0.08% polyethylene glycol 600 is added to the water in step (1).
Preferably, in step (2) the portion of codonopsis pilosula is 70-85% codonopsis pilosula.
Preferably, the mass ratio of the concentrated filtrate to the probiotic powder in step (3) is 1:0.5-1.5%.
Preferably, the probiotics in the step (3) comprise lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 in a mass ratio of 1:2-4; the fermentation temperature is 30-36 ℃ and the fermentation time is 24-48h.
The lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 are compounded and subjected to liquid medicine fermentation, so that the lactobacillus plantarum STN26 has good effects of regulating blood lipid metabolism, removing free radicals in bodies and regulating intestinal flora, and the supplier is Jia Yi bioengineering Co., ltd.
It is also an object of the present invention to provide the use of the above composition for the preparation of a product for the treatment of hyperlipidemia.
Compared with the prior art, the invention has the beneficial effects that:
(1) The invention adopts scientific proportion, the tarragon is bitter and pungent, is slightly cold, clears heat and promotes diuresis, and eliminates jaundice, and is reused as a monarch. Oriental Waterplantain rhizome has the effects of promoting diuresis, removing dampness, relieving heat, eliminating turbid pathogen and reducing blood lipid; rhizoma anemarrhenae nourishes yin, reduces pathogenic fire, moistens dryness and smoothes intestines, and the two medicines are assistant with monarch drugs to induce diuresis to alleviate edema and relieve the monarch drugs from purging excessive fire to hurt body fluid, and are ministerial drugs. Poria cocos, radix stephaniae tetrandrae induce diuresis and alleviate edema; detoxification and detumescence of red bean; radix trichosanthis helps rhizoma anemarrhenae to promote salivation and clear fire; cortex moutan and herba Lycopi have effects of promoting blood circulation for removing blood stasis, clearing heat, cooling blood, and inducing diuresis for removing edema; the radix codonopsis can tonify qi and blood, enter the organism to promote qi and blood circulation, enable the medicines to directly reach the internal organs, play a role in overall regulation and tonification, and are used as adjuvant medicines together. The medicines together play roles of clearing heat and promoting diuresis, nourishing yin and moisturizing dryness, promoting qi and activating blood circulation, regulating viscera functions of human bodies, and transforming ointment and fat.
(2) The invention achieves good blood lipid reducing effect through the synergistic compatibility of the medicinal herbs, has more remarkable blood lipid regulating effect compared with the positive control medicine, can regulate the organism through multiple components, multiple targets and multiple layers, has no drug resistance, no toxic or side effect and good compliance of patients after long-term administration.
(3) According to the invention, the moutan bark, the poria cocos and the alisma are soaked in the vinegar for more than half an hour before being extracted, so that the extraction of active ingredients is more complete, the heating extraction time is obviously shortened, and the retention of heat-sensitive active ingredients is more beneficial.
(4) The invention uses special probiotic composition to ferment the extracting solution, promotes the generation of new metabolites of the extracting solution and the increase of the concentration of active ingredients, and in addition, the probiotics can be used for regulating intestinal probiotics flora and regulating body fat metabolism in cooperation with dry paste powder, thereby enhancing the lipid-lowering curative effect of the formula of the invention.
Detailed Description
The invention is further described in connection with the following detailed description. The following raw materials are all commercially available conventional materials. The Chinese medicinal materials are derived from Chinese medicinal material market or pharmacy, the supplier of probiotic raw materials is Jiayi bioengineering limited company in Shandong, vinegar is edible rice vinegar, and polyethylene glycol 600 is medicinal conventional adjuvant.
Example 1:
the raw materials of the embodiment are as follows: 5.6 parts of herba artemisiae scopariae, 5 parts of rhizoma anemarrhenae, 4.2 parts of cortex moutan, 5 parts of rhizoma alismatis, 2.8 parts of poria cocos, 2.8 parts of radix stephaniae tetrandrae, 2 parts of herba lycopi, 1.4 parts of radix trichosanthis, 5 parts of radix codonopsis and 1.4 parts of red bean.
The preparation method comprises the following steps:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar at 40deg.C for 40min, filtering, mixing with herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, adding 5 times of water, adding polyethylene glycol 600 to water concentration of 0.05%, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli, extracting with 8 times of water relative to the total mass of rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli for 1 hr, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting at 35deg.C for 2 days, and drying the fermentation broth under reduced pressure. Wherein the probiotics are compounded by lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 according to the mass ratio of 1:2.
Example 2:
The raw materials of the embodiment are as follows: 3.5 parts of herba artemisiae scopariae, 1 part of rhizoma anemarrhenae, 3 parts of cortex moutan, 3 parts of rhizoma alismatis, 2 parts of poria cocos, 2 parts of radix stephaniae tetrandrae, 1.5 parts of herba lycopi, 3.2 parts of radix trichosanthis, 3.8 parts of radix codonopsis, and 2.0 parts of red bean.
The preparation method comprises the following steps:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar at 50deg.C for 60min, removing vinegar, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, adding 8 times of water, adding polyethylene glycol 600 to water concentration of 0.08%, decocting for 0.5 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 75% radix Codonopsis and semen Phaseoli, extracting with water 5 times of the total mass of rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 75% radix Codonopsis and semen Phaseoli for 1 hr, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting at 30deg.C for 2 days, and drying the fermentation broth under reduced pressure. Wherein the probiotics are compounded by lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 according to the mass ratio of 1:4.
Example 3:
the raw materials of the embodiment are as follows: 5.6 parts of herba artemisiae scopariae, 3.5 parts of rhizoma anemarrhenae, 5 parts of cortex moutan, 8 parts of rhizoma alismatis, 4 parts of poria cocos, 4 parts of radix stephaniae tetrandrae, 3 parts of herba lycopi, 3 parts of radix trichosanthis, 6.8 parts of radix codonopsis and 4.2 parts of red bean.
The preparation method comprises the following steps:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar at 55deg.C for 60min, removing vinegar, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, adding 8 times of water, adding polyethylene glycol 600 to water concentration of 0.05%, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli, extracting with 8 times of water relative to the total mass of rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli for 1 hr, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting at 36deg.C for 1 day, and drying the fermentation broth under reduced pressure. Wherein the probiotics are compounded by lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 according to the mass ratio of 1:3.
Comparative example 1
The comparative example differs from example 1 in that the prescription has different medicinal flavors, and the specific composition is as follows: 5.6 parts of virgate wormwood herb, 5 parts of anemarrhena rhizome, 4.2 parts of turmeric root-tuber, 5 parts of oriental waterplantain rhizome, 2.8 parts of Indian buead, 2.8 parts of giant knotweed rhizome, 2 parts of red paeony root, 1.4 parts of mongolian snakegourd root, 5 parts of pilose asiabell root and 1.4 parts of red bean.
The preparation method comprises the following steps:
(1) Soaking radix Curcumae, alismatis rhizoma, and Poria in vinegar at 40deg.C for 40min, filtering, mixing with herba Artemisiae Scopariae and rhizoma Polygoni Cuspidati, adding 5 times of water, adding polyethylene glycol 600 to water concentration of 0.05%, decocting for 1 hr, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, radix Paeoniae Rubra, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli, extracting with 8 times of water relative to the total mass of rhizoma anemarrhenae, radix Paeoniae Rubra, radix Trichosanthis, 85% radix Codonopsis and semen Phaseoli for 1 hr, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting at 35deg.C for 2 days, and drying the fermentation broth under reduced pressure. Wherein the probiotics are compounded by lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 according to the mass ratio of 1:2.
Comparative example 2
The difference between the comparative example and the example 1 is that probiotics are different, and the probiotics are specifically compounded by lactobacillus plantarum JYLP-002 and streptococcus thermophilus JYST-26 in a mass ratio of 1:2.
Comparative example 3
The difference between this comparative example and example 1 is that the preparation method adopts the traditional decocting. The preparation method comprises the following steps:
(1) Adding water 5 times of the total mass of the above materials into cortex moutan, alismatis rhizoma, poria, herba Artemisiae Scopariae, radix Stephaniae Tetrandrae, rhizoma anemarrhenae, herba Lycopi, trichosanthis radix, radix Codonopsis and semen Phaseoli, adding polyethylene glycol 600 to concentration of 0.05%, decocting for 0.5 hr, decocting for 3 times, filtering, and mixing filtrates;
(3) Concentrating the filtrate, adding probiotic powder, fermenting at 35deg.C for 2 days, and drying the fermentation broth under reduced pressure. Wherein the probiotics are compounded by lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 according to the mass ratio of 1:2.
Hypolipidemic pharmacodynamic experiments
90 SD healthy male rats are selected, after the animal house is adaptively fed for one week, 10 normal rats are fed with normal feed, and the rest rats are fed with high-fat feed (the basic feed is 60%, the lard is 10%, the sucrose is 20%, the cholesterol is 5% and the sodium cholate is 5% mixed), and the rats drink water freely. After feeding for 4 weeks, the body weight was weighed to prepare a hyperlipoidemia rat model. The hyperlipidemia rats were then divided into 8 groups according to a random number table, which were model group, positive group, examples 1 to 3 groups, comparative examples 1 to 3 groups, respectively.
Gastric lavage administration:
The compositions prepared in the corresponding groups of the examples 1-3 and the comparative examples 1-3 are added, and the administration dosage is 15g/kg of crude drug, and the compositions are dissolved and dispersed by adding water; the model group and the normal group were respectively given the same dose of physiological saline, and the positive group was perfused with 1.5mg/kg of simvastatin suspension. After 3 weeks of gastric lavage, no water is forbidden for 12 hours, and blood is taken to determine the levels of total triglycerides, total cholesterol, low density lipoproteins and high density lipoproteins in serum. The experimental data were all statistically processed using SPSS13.0 software, the index values were expressed as mean.+ -. Standard deviation, and the comparisons between groups were t-checked. The results are shown in Table 1.
TABLE 1 Effect of the inventive formula on blood lipid metabolism
Note that: * The expression is statistically significant compared with the blank group, P < 0.05; # represents statistically significant, # P < 0.05 compared to the model group; delta represents that, compared with the group of example 1, it is statistically significant that DeltaP < 0.05.
Analysis of results: as can be seen from comparison of the model group and the blank group, after the model rat is fed with high fat 3, the blood fat biochemical index of the model rat is obviously higher than that of the normal group, and the model rat has obvious statistical difference (P is less than 0.05), which indicates that the model building is successful. After the lipid-lowering composition is administered to model animals for 3 weeks, the levels of total cholesterol, triglyceride and low-density lipoprotein in the blood of rats are obviously reduced, and the levels of the high-density lipoprotein are greatly increased, which indicates that the composition can effectively regulate the blood lipid metabolism in patients with hyperlipidemia. Compared with the example 1, the comparative example 1 has changed monarch drug, part of adjuvant drug adopts drug taste control with similar efficacy in traditional Chinese medicine, the treatment effect is not good, the comparative example 2 adopts other probiotics for fermentation, the comparative example 3 adopts traditional combined decoction method for extraction, and the lipid-lowering efficacy of the prepared composition is not as strong as the invention. The composition has outstanding efficacy in lipid lowering, can achieve the efficacy equivalent to that of simvastatin medicines, avoids the risks of adverse reactions such as rhabdomyolysis and the like, has good compliance of patients, and is suitable for long-term administration.
The foregoing detailed description is directed to one of the possible embodiments of the present invention, which is not intended to limit the scope of the invention, but is to be accorded the full scope of all such equivalents and modifications so as not to depart from the scope of the invention.
Claims (5)
1. The composition for treating the hyperlipidemia is characterized by comprising the following raw materials in parts by weight: 1-10 parts of rhizoma anemarrhenae, 3-8 parts of cortex moutan, 1-10 parts of rhizoma alismatis, 1-5 parts of poria cocos, 1-5 parts of radix stephaniae tetrandrae, 1-5 parts of herba lycopi, 1-5 parts of radix trichosanthis, 1-10 parts of radix codonopsis, 1-10 parts of artemisia capillaris and 1-5 parts of red bean;
The preparation method of the composition comprises the following steps:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar, filtering, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, extracting with water, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, part of radix Codonopsis and semen Phaseoli, extracting with water, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting, and drying;
wherein the temperature of the vinegar soaking in the step (1) is 40-55 ℃, and the soaking time is 40-60min; adding 0.05-0.08% of polyethylene glycol 600 into the water;
The part of the dangshen in the step (2) is 70-85 percent of dangshen;
the mass ratio of the concentrated filtrate to the probiotic powder in the step (3) is 1:0.5-1.5%; the probiotic powder is lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 with the mass ratio of 1:2-4; the fermentation temperature is 30-36 ℃ and the fermentation time is 24-48h.
2. The composition according to claim 1, wherein the raw materials of the composition are the following components in parts by weight: 1-5 parts of rhizoma anemarrhenae, 3-5 parts of cortex moutan, 3-8 parts of rhizoma alismatis, 2-4 parts of poria cocos, 2-4 parts of radix stephaniae tetrandrae, 1-3 parts of herba lycopi, 1-5 parts of radix trichosanthis, 3-8 parts of radix codonopsis, 3-8 parts of artemisia capillaris and 1-5 parts of red bean.
3. The composition according to claim 1, wherein the raw materials of the composition are the following components in parts by weight: 5 parts of rhizoma anemarrhenae, 4.2 parts of moutan bark, 5 parts of rhizoma alismatis, 2.8 parts of poria cocos, 2.8 parts of radix stephaniae tetrandrae, 2 parts of herba lycopi, 1.4 parts of radix trichosanthis, 5 parts of radix codonopsis, 5.6 parts of herba artemisiae scopariae and 1.4 parts of red bean.
4. A process for the preparation of a composition as claimed in any one of claims 1 to 3, comprising the steps of:
(1) Soaking cortex moutan, alismatis rhizoma, and Poria in vinegar, filtering, adding herba Artemisiae Scopariae and radix Stephaniae Tetrandrae, extracting with water, and filtering to obtain residue 1 and filtrate 1;
(2) Mixing the residue 1 with rhizoma anemarrhenae, herba Lycopi, radix Trichosanthis, part of radix Codonopsis and semen Phaseoli, extracting with water, and filtering to obtain filtrate 2;
(3) Mixing filtrate 1 and filtrate 2, concentrating, adding the rest radix Codonopsis powder, mixing, adding probiotic powder, fermenting, and drying;
wherein the temperature of the vinegar soaking in the step (1) is 40-55 ℃, and the soaking time is 40-60min; adding 0.05-0.08% of polyethylene glycol 600 into the water;
The part of the dangshen in the step (2) is 70-85 percent of dangshen;
the mass ratio of the concentrated filtrate to the probiotic powder in the step (3) is 1:0.5-1.5%; the probiotic powder is lactobacillus plantarum JYLP-326 and streptococcus thermophilus STN26 with the mass ratio of 1:2-4; the fermentation temperature is 30-36 ℃ and the fermentation time is 24-48h.
5. Use of a composition according to any one of claims 1-3 for the preparation of a product for the treatment of hyperlipidemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210337079.1A CN116920039B (en) | 2022-03-31 | 2022-03-31 | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210337079.1A CN116920039B (en) | 2022-03-31 | 2022-03-31 | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116920039A CN116920039A (en) | 2023-10-24 |
| CN116920039B true CN116920039B (en) | 2024-05-17 |
Family
ID=88383083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210337079.1A Active CN116920039B (en) | 2022-03-31 | 2022-03-31 | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116920039B (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028438A (en) * | 2007-04-10 | 2007-09-05 | 方云朝 | Capsule for treating diabetes |
| CN103750304A (en) * | 2013-12-30 | 2014-04-30 | 青岛恒波仪器有限公司 | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof |
| CN104740517A (en) * | 2013-12-27 | 2015-07-01 | 盖春美 | Traditional Chinese medicine for treating hyperlipidemia |
| CN105395842A (en) * | 2015-11-09 | 2016-03-16 | 长葛市新世纪机电有限公司 | Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof |
| CN107296914A (en) * | 2017-08-07 | 2017-10-27 | 石林星 | It is a kind of to treat Chinese medicine composition of hypertension and preparation method thereof |
| CN111514195A (en) * | 2020-06-09 | 2020-08-11 | 江苏省中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof |
-
2022
- 2022-03-31 CN CN202210337079.1A patent/CN116920039B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028438A (en) * | 2007-04-10 | 2007-09-05 | 方云朝 | Capsule for treating diabetes |
| CN104740517A (en) * | 2013-12-27 | 2015-07-01 | 盖春美 | Traditional Chinese medicine for treating hyperlipidemia |
| CN103750304A (en) * | 2013-12-30 | 2014-04-30 | 青岛恒波仪器有限公司 | Weight-reducing, fat-reducing and health-protection rhizoma alismatis oral liquid and preparation method thereof |
| CN105395842A (en) * | 2015-11-09 | 2016-03-16 | 长葛市新世纪机电有限公司 | Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof |
| CN107296914A (en) * | 2017-08-07 | 2017-10-27 | 石林星 | It is a kind of to treat Chinese medicine composition of hypertension and preparation method thereof |
| CN111514195A (en) * | 2020-06-09 | 2020-08-11 | 江苏省中医院 | Traditional Chinese medicine composition for treating non-alcoholic fatty liver disease and preparation method and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 120例非酒精性脂肪肝单元证特点分析与健脾清肝方临床疗效;周滔;等;中西医结合肝病杂志;20090828;第19卷(第04期);第209-210页 * |
| 六味地黄丸加减治疗高血脂症;张琨;等;中国民族民间医药;20110115;第-卷(第01期);第117页 * |
| 单味中药防治糖尿病的现代研究探讨;赵红霞;等;中国医药导刊;20131015;第15卷(第10期);第1692-1694页 * |
| 茯苓泽泻加山楂汤对高脂血症早期干预的实验研究;展照双;等;山东中医杂志;20061020;第25卷(第10期);第693-695页 * |
| 高脂血症的中药治疗;何国权;河南中医;20040310;第23卷(第03期);第59-60页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116920039A (en) | 2023-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101513437B (en) | Antifatigue Chinese pharmaceutical composition and preparation method thereof | |
| CN1586544A (en) | Medicinal wine and its producing method | |
| CN104491759B (en) | A kind of Chinese medicine composition for treating antimigraine and preparation method thereof | |
| CN104922550A (en) | Traditional Chinese medicine combination and application thereof | |
| CN107412665B (en) | It is a kind of that there is Chinese medicine composition for relieving the effect of alcohol, preventing alcoholic liver injury and its preparation method and application | |
| CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
| CN118044611A (en) | Lung-clearing and lung-protecting nutrition product | |
| CN116920039B (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method thereof | |
| CN115969909B (en) | Traditional Chinese medicine composition and fermented traditional Chinese medicine preparation for improving sub-health of sow as well as preparation method and application of traditional Chinese medicine composition and fermented traditional Chinese medicine preparation | |
| CN105902827A (en) | Traditional Chinese medicine composition for improving immunity of human body and preparation method thereof | |
| CN1211434A (en) | Oral liquid for resisting altitude stress and its preparation method | |
| CN104825821A (en) | Medicine for treating diabetes and preparation method thereof | |
| CN116098981A (en) | Medicinal and edible traditional Chinese medicine composition for reducing blood fat and preparation method thereof | |
| CN106377700A (en) | Folium mori and bitter gourd tea and making method thereof | |
| CN114698841A (en) | Herbal extract for promoting blood circulation and improving sub-health | |
| CN112402569A (en) | Anti-fatigue health product and preparation method thereof | |
| CN112641878A (en) | Traditional Chinese medicine composition for treating anemia and preparation method thereof | |
| CN111471562A (en) | Motherwort wine and preparation method thereof | |
| CN115531487B (en) | Compound agent for improving immune globulin and superoxide dismutase and preparation method thereof | |
| CN118767063B (en) | Traditional Chinese medicine composition for treating cardiovascular diseases, preparation method and application | |
| CN110038087A (en) | It is a kind of to consolidate lengthen one's life Chinese medicine composition and its liquid medicine being prepared and application | |
| CN118767025B (en) | Children's traditional Chinese medicine ointment for strengthening spleen and replenishing qi, promoting body fluid and stimulating appetite and preparation method thereof | |
| CN108186874B (en) | A Chinese medicinal composition for treating diabetes | |
| CN119700901A (en) | A dehumidifying ointment and its preparation method | |
| CN106668428A (en) | Blood sugar reducing traditional Chinese medicine composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |